Authors
Latest:
Dr. Graziano on Sequencing Targeted Therapy in NSCLCStephen L. Graziano, MD, professor of medicine, division chief of medicine, and division chief of Upstate Cancer Center Adult Hematology/Oncology at the Upstate University Hospital, discusses sequencing targeted therapy for patients with non–small cell lung cancer (NSCLC).
Latest:
Future Directions in Treatment of Small Cell Lung CancerPanelists conclude their discussion by commenting on areas of unmet need and sharing personal perspectives on factors that may change clinical practice for SCLC in the future.
Latest:
Experts Highlight Their Biggest Takeaways from the 2023 SOHO Annual MeetingKey opinion leaders from across the hematologic oncology realm shared their biggest takeaways from the 2023 SOHO Annual Meeting.
Latest:
Myeloproliferative Neoplasm Management: Future Directions in CareClosing out their discussion on myeloproliferative neoplasms, key opinion leaders share excitement for future evolutions in the treatment paradigm.
Latest:
Dr Opat on the Accessibility of Sonrotoclax Plus Zanubrutinib in R/R CLL/SLLStephen Opat, MBBS, discusses the accessibility of sonrotoclax plus zanubrutinib in relapsed/refractory chronic lymphocytic leukemia or small lymphocytic lymphoma.
Latest:
Dr. Stephen Grubbs on Measuring Value in OncologyStephen S. Grubbs, MD, senior director of the new clinical affairs department of the American Society of Clinical Oncology (ASCO) discusses value-based oncology.
Latest:
Dr. Stilgenbauer on Activity With Venetoclax in Patients With CLLStephen Stilgenbauer, MD, associate professor, Department of Haematology, Oncology, Rheumatology and Infectious Diseases, University of Ulm, Germany, discusses the clinical activity seen with venetoclax in patients with chronic lymphocytic leukemia, according to results of the open-label, single-arm, multicenter M13-982 study.
Latest:
Dr. Williams on the Rationale for the SunRISE-2 Trial in Muscle-Invasive Bladder CancerStephen B. Williams, MD, discusses the rationale for the phase 3 SunRISE-2 trial in muscle-invasive bladder cancer.
Latest:
Dr. Gonzalez on Cost-Benefit of Treating Hepatitis C in HCC Patients Before TransplantStevan A. Gonzalez, MD MS, clinical assistant professor, department of internal medicine, Texas A&M College of Medicine, medical director of liver transplantation, Simmons Transplant Institute, Baylor All Saints Medical Center, discusses a cost effectiveness analysis of treating hepatitis C patients with hepatocellular carcinoma (HCC) before or after a liver transplant.
Latest:
Everolimus Shows Robust Activity in Lung/GI NETsEverolimus improved progression-free survival by 7.1 months compared with placebo in patients with lung/gastrointestinal (GI) neuroendocrine tumors, representing a 52% reduction in the risk of progression or death.
Latest:
Dr. Fischkoff on Vision for TIL Therapy in MelanomaSteven A. Fischkoff, MD, chief medical officer of Lion Biotechnologies, Inc, discusses his vision for tumor-infiltrating lymphocyte therapy for patients with melanoma.
Latest:
Dr. Steven Rosenberg on the Curative Potential of Adoptive Cell TherapySteven A. Rosenberg, MD, PhD, chief, Surgery Branch, senior investigator, head, Tumor Immunology Section, National Cancer Institute, explains advancements in adoptive cell therapy for the treatment of melanoma.
Latest:
Therapy of Non-Small Cell Lung Cancer: Past, Present, and FutureNew and relevant studies are examining the role of histology, biomarkers, and growth factor receptor inhibitors in the treatment of NSCLC.
Latest:
Dr. Toms on Targeting MEK as a Treatment Strategy for CNS MetastasisSteven A. Toms, MD, director, neurosurgery, Geisinger Health System, discusses how targeting MEK can be an effective treatment strategy for CNS metastasis.
Latest:
Steven Buechler Discusses EarlyR Gene Signature in the BIG 1-98 Trial for Breast CancerSteven Buechler, PhD, Department of Applied and Computational Mathematics and Statistics at the University of Notre Dame, discusses independent validation of the EarlyR gene signature in the Breast International Group (BIG) 1-98 study. This randomized, double-blind, phase III trial compared letrozole with tamoxifen as an adjuvant endocrine therapy for postmenopausal women with hormone receptor-positive, early breast cancer
Latest:
Dr. Campbell Discusses the Goals of the New RCC GuidelinesSteven Campbell, MD, PhD, urologist, Cleveland Clinic, discusses the goals of the newly updated guidelines in renal cell carcinoma.
Latest:
Dr. Coutre Discusses Combination Strategies in ALLSteven Coutre, MD, professor of medicine at Stanford University Medical Center, discusses combination strategies for the treatment of patients with acute lymphoblastic leukemia (ALL).
Latest:
CLL: Final ThoughtsAn expert panel provides their final thoughts about the future of the chronic lymphocytic leukemia (CLL) treatment landscape.
Latest:
Clinician's View: Making Survival a Blessing, Not a BurdenMore and more deadly diseases are slowly being transformed into chronic conditions. This is especially true of cancer.
Latest:
Hypofractionated and Stereotactic Body Radiotherapy in Prostate CancerDespite limited data comparing stereotactic body radiation therapy to standard or hypofractionated radiotherapy with regards to long-term clinical outcomes and toxicity profiles, the data are promising and appropriately selected patients can be offered such an approach off-protocol.
Latest:
Shooting for the Moon…and BeyondThis is an exciting time, as reports of major news impacting oncology research are emerging, it seems, on a daily basis.
Latest:
Radiation Therapy, Chemotherapy, Targeted Therapy, and Possibly Immunotherapy in Localized SarcomaAs clinicians have gained an improved understanding of the biology of soft-tissue sarcoma malignancies, the ability to better distinguish and identify subtypes has extended the hope of targeted treatment options.
